Industry Focus

These two biopharma heavyweights are taking it on the chin following a market-trouncing performance in 2017. Is one a better stock to buy than the other? 

Direct download: 20180207_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST

1